Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab

Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus (DM) and is characterized by hyperglycemia, hyperketonemia and metabolic acidosis. With the increasing use of immune checkpoint inhibitors (ICIs), such as pembrolizumab in cancer therapy, it’s important tound...

Full description

Bibliographic Details
Published in:Liječnički vjesnik
Main Authors: Karla Lauš, Hrvoje Centner, Ema Schönberger, Silvija Canecki-Varžić
Format: Article
Language:English
Published: Hrvatski liječnički zbor 2023-01-01
Subjects:
diabetes mellitus
diabetic ketoacidosis
pembrolizumab
Online Access:https://hrcak.srce.hr/file/437681
Description
Summary:Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus (DM) and is characterized by hyperglycemia, hyperketonemia and metabolic acidosis. With the increasing use of immune checkpoint inhibitors (ICIs), such as pembrolizumab in cancer therapy, it’s important tounderstand immune-related adverse events that comes with it.
ISSN:0024-3477
1849-2177

Similar Items